Galapagos

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: Public

Established: 1999-01-01

Employees: 1.1K

Market Cap: $1.9B

Website: http://www.glpg.com

Introduction: Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Clinical Trials

A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis

Phase 2

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: GLPG2222 300 mg q.d.
Drug: Placebo
Drug: GLPG2222 150 mg q.d.

First Posted Date: 2017-02-07

Last Posted Date: 2017-11-21

Lead Sponsor: Galapagos NV

Target Recruit Count: 37

Registration Number: NCT03045523

Locations: 🇦🇺
Westmead Hospital, Westmead, Australia
🇧🇪
UZ Leuven, Leuven, Belgium
🇦🇺
The Prince Charles Hospital, Chermside, Australia

and more 19 locations

Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease

Phase 3

Completed

Conditions: Crohn's Disease

Interventions: Drug: Filgotinib
Other: Placebo

First Posted Date: 2016-09-26

Last Posted Date: 2023-12-18

Lead Sponsor: Galapagos NV

Target Recruit Count: 1372

Registration Number: NCT02914561

Locations: 🇺🇸
Massachusetts General Hospital - Crohn's and Colitis Center, Boston, Massachusetts, United States
🇺🇸
Kelsey-Seybold Clinic, Houston, Texas, United States
🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States

and more 509 locations

Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

Phase 3

Active, not recruiting

Conditions: Ulcerative Colitis

Interventions: Drug: Filgotinib
Drug: Placebo

First Posted Date: 2016-09-26

Last Posted Date: 2023-11-27

Lead Sponsor: Galapagos NV

Target Recruit Count: 1173

Registration Number: NCT02914535

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
University of Miami Crohn's and Colitis Center, Miami, Florida, United States
🇺🇸
Cordova Research Institute, Miami, Florida, United States

and more 320 locations

Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease

Phase 3

Terminated

Conditions: Crohn's Disease

Interventions: Drug: Filgotinib
Drug: Placebo

First Posted Date: 2016-09-26

Last Posted Date: 2024-07-10

Lead Sponsor: Galapagos NV

Target Recruit Count: 1188

Registration Number: NCT02914600

Locations: 🇺🇸
NYU Langone Long Island Clinical Research Associates, Great Neck, New York, United States
🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸
Kelsey-Seybold Clinic, Houston, Texas, United States

and more 481 locations

Bioavailability Study With GLPG1972

Phase 1

Completed

Conditions: Osteoarthritis

Interventions: Drug: GLPG1972 600 mg oral solution fasted
Drug: GLPG1972 600 mg oral tablet fasted
Drug: GLPG1972 600 mg oral tablet fed

First Posted Date: 2016-08-01

Last Posted Date: 2016-10-04

Lead Sponsor: Galapagos NV

Target Recruit Count: 12

Registration Number: NCT02851485

Locations: 🇳🇱
PRA-EDS, Zuidlaren, Netherlands

A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2451 in Healthy Female Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: GLPG2451 single dose

First Posted Date: 2016-06-02

Last Posted Date: 2017-07-12

Lead Sponsor: Galapagos NV

Target Recruit Count: 31

Registration Number: NCT02788721

Locations: 🇧🇪
SGS LSS Clinical Pharmacology Unit Antwerp, Antwerp, Belgium

First in Human of Single and Multiple Doses of MOR106

Phase 1

Completed

Conditions: Healthy
Dermatitis, Atopic

Interventions: Drug: Placebo single ascending doses, intravenous
Drug: MOR106 multiple ascending doses, intravenous
Drug: MOR106 single ascending doses, intravenous
Drug: Placebo multiple intravenous administrations

First Posted Date: 2016-04-14

Last Posted Date: 2017-10-05

Lead Sponsor: Galapagos NV

Target Recruit Count: 81

Registration Number: NCT02739009

Locations: 🇲🇩
• Arensia Phase I unit, Chisinau, Moldova, Republic of
🇧🇪
SGS LSS Clinical Pharmacology Unit, Antwerp, Belgium
🇷🇴
Arensia Phase I unit, Bucharest, Romania

and more 1 locations

Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Phase 2

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Placebo QD
Drug: GLPG1690 600 mg QD

First Posted Date: 2016-04-14

Last Posted Date: 2020-11-06

Lead Sponsor: Galapagos NV

Target Recruit Count: 23

Registration Number: NCT02738801

Locations: 🇺🇦
F.G. Yanovskyy Institute of Phthisiatry and Pulmonology 2, Kiev, Ukraine
🇺🇦
Municipal Clinical Hospital # 6, Dnipropetrovsk, Ukraine
🇺🇦
Kharkov City Clinical Hospital # 13, Kharkov, Ukraine

and more 5 locations

Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation)

Phase 2

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: GLPG1837 dose 1
Drug: GLPG1837 dose 2
Drug: GLPG1837 dose 3

First Posted Date: 2016-03-14

Last Posted Date: 2016-12-07

Lead Sponsor: Galapagos NV

Target Recruit Count: 26

Registration Number: NCT02707562

Locations: 🇦🇺
Royal Adelaide Hospital, Adelaide, Australia
🇦🇺
The Prince Charles Hospital, Chermside, Australia
🇦🇺
Monash Medical Centre, Clayton, Australia

and more 13 locations

Study of GLPG1837 in Subjects With Cystic Fibrosis (S1251N Mutation)

Phase 2

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: GLPG1837 dose 1
Drug: GLPG1837 dose 2

First Posted Date: 2016-02-24

Last Posted Date: 2016-10-11

Lead Sponsor: Galapagos NV

Target Recruit Count: 7

Registration Number: NCT02690519

Locations: 🇧🇪
University Hospital Antwerp, Antwerp, Belgium
🇧🇪
University Hospital Ghent, Ghent, Belgium
🇧🇪
University Hospitals Leuven, Leuven, Belgium

and more 2 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy